Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (4438)	6/5/1998 9:22:00 AM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

To all: Can anyone point to a source for either the actual report or even a synopsis of Agouron's evaluation of Phase I trials of AG3340? A number of biotechs seem to release information of remarkable incidental efficacy observed in patients - during the course of their Phase I trials. Thanks. To Dave S: I have previously posted two evaluation models. Both suggest that AGPH is grossly undervalued - in as much current price discounts R&D expenses but assumes no potential revenue from the pipeline before 2000- 2001. As I have argued previously, on that basis hundreds of biotechs should have a market capitalization of zero.